TEMPUS AI INC (TEM) Stock Fundamental Analysis
NASDAQ:TEM - Nasdaq - US88023B1035 - Common Stock
Taking everything into account, TEM scores 2 out of 10 in our fundamental rating. TEM was compared to 56 industry peers in the Life Sciences Tools & Services industry. TEM may be in some trouble as it scores bad on both profitability and health. TEM is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
TEM had negative earnings in the past year.
1.2 Ratios
The Return On Assets of TEM (-102.84%) is worse than 94.64% of its industry peers.
Looking at the Return On Equity, with a value of -1859.89%, TEM is doing worse than 94.64% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -102.84% | ||
| ROE | -1859.89% | ||
| ROIC | N/A |
ROA(3y)-52.03%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
TEM has a better Gross Margin (53.22%) than 64.29% of its industry peers.
TEM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.22% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
TEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TEM remains at a similar level compared to 1 year ago.
Compared to 1 year ago, TEM has a worse debt to assets ratio.
2.2 Solvency
TEM has an Altman-Z score of 0.56. This is a bad value and indicates that TEM is not financially healthy and even has some risk of bankruptcy.
TEM has a worse Altman-Z score (0.56) than 71.43% of its industry peers.
TEM has a Debt/Equity ratio of 8.17. This is a high value indicating a heavy dependency on external financing.
TEM's Debt to Equity ratio of 8.17 is on the low side compared to the rest of the industry. TEM is outperformed by 94.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 8.17 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.56 |
ROIC/WACCN/A
WACC10.53%
2.3 Liquidity
TEM has a Current Ratio of 2.69. This indicates that TEM is financially healthy and has no problem in meeting its short term obligations.
TEM has a Current ratio (2.69) which is comparable to the rest of the industry.
TEM has a Quick Ratio of 2.55. This indicates that TEM is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.55, TEM is in line with its industry, outperforming 53.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.69 | ||
| Quick Ratio | 2.55 |
3. Growth
3.1 Past
TEM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.35%, which is quite impressive.
The Revenue has grown by 65.85% in the past year. This is a very strong growth!
EPS 1Y (TTM)20.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)65.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, TEM will show a very strong growth in Earnings Per Share. The EPS will grow by 27.44% on average per year.
Based on estimates for the next years, TEM will show a very strong growth in Revenue. The Revenue will grow by 33.70% on average per year.
EPS Next Y-97.38%
EPS Next 2Y24.85%
EPS Next 3Y27.44%
EPS Next 5YN/A
Revenue Next Year32.7%
Revenue Next 2Y35.7%
Revenue Next 3Y33.7%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for TEM. In the last year negative earnings were reported.
Also next year TEM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as TEM's earnings are expected to grow with 27.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.85%
EPS Next 3Y27.44%
5. Dividend
5.1 Amount
TEM does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TEMPUS AI INC
NASDAQ:TEM (1/21/2025, 8:00:02 PM)
Premarket: 54.84 +7.2 (+15.11%)47.64
+12.49 (+35.53%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners27.59%
Inst Owner Change-0.13%
Ins Owners38.14%
Ins Owner Change0.49%
Market Cap7.50B
Analysts80
Price Target60.75 (27.52%)
Short Float %13.51%
Short Ratio2.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.09%
Min EPS beat(2)20.15%
Max EPS beat(2)52.02%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1%
Min Revenue beat(2)-0.22%
Max Revenue beat(2)2.21%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.22%
PT rev (3m)29.87%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 7.32 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 139.61 | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-9.49
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS6.51
BVpS0.34
TBVpS-0.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -102.84% | ||
| ROE | -1859.89% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 53.22% | ||
| FCFM | N/A |
ROA(3y)-52.03%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover1.05
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 8.17 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.69 | ||
| Quick Ratio | 2.55 | ||
| Altman-Z | 0.56 |
F-ScoreN/A
WACC10.53%
ROIC/WACCN/A
Cap/Depr(3y)71.18%
Cap/Depr(5y)N/A
Cap/Sales(3y)5.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-97.38%
EPS Next 2Y24.85%
EPS Next 3Y27.44%
EPS Next 5YN/A
Revenue 1Y (TTM)65.85%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year32.7%
Revenue Next 2Y35.7%
Revenue Next 3Y33.7%
Revenue Next 5YN/A
EBIT growth 1Y26.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year46.54%
EBIT Next 3Y30.93%
EBIT Next 5YN/A
FCF growth 1Y-33.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-27.43%
OCF growth 3YN/A
OCF growth 5YN/A